Direct-to-consumer telehealth companies have grown rapidly in response to patients demand for GLP-1s like semaglutide and tirzepatide, especially after shortages created a market for compounded versions that arent approved by the Food and Drug Administration

For patients interested in participating in research , the following resources may be helpful: NIHR Be Part of Research (bepartofresearch.nihr.ac.uk) search for Parkinson's and GLP-1 trials Parkinson's UK (www.parkinsons.org.uk) information on current research and trial opportunities When to contact your GP or specialist : If you have Parkinson's disease and diabetes, and wish to discuss whether a GLP-1 receptor agonist is appropriate for your diabetes management If you experience new or worsening symptoms whilst taking any medication If you are interested in clinical trial participationyour neurologist can advise on suitable studies Seek urgent medical attention if you experience: Severe, persistent abdominal pain (possible pancreatitis) Persistent vomiting or inability to keep fluids down (risk of dehydration) Signs of dehydration (extreme thirst, dark urine, dizziness) Allergic reaction (rash, swelling, difficulty breathing) Patients should never start, stop, or modify medications without medical supervision

Ozempic pens are designed to deliver pre-set doses of 0.25 mg, 0.5 mg, 1 mg, or 2 mg through the pen's dose selector, eliminating the need for manual unit calculations
Semaglutide vs Tirzepatide in Reviews Some reviews compare semaglutide and tirzepatide because both are used in GLP-1 weight-loss programs
X.EricssonM.RabashaB.BudnikB.ChanS
UK-based research supplier focused on quality presentation and traceability